Pete Conley, Know Labs’ CFO and SVP of IP, will share his perspective into why a strategically developed IP portfolio serves as the foundation for long-term value creation

Know Labs (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced that Pete Conley, its Chief Financial Officer and Senior Vice President of Intellectual Property (IP), will speak at the upcoming 2023 Intellectual Property Business Congress (IPBC) Global event in June – the world’s largest gathering of leaders and decision-makers operating in the global IP market.

Mr. Conley is participating as a panelist in a discussion titled, “Make Your CFO an IP Believer,” with other IP leaders from HP, Uber, and Deloitte. With over 35 years of experience at the intersection of IP-related corporate finance, investment banking, and the forecasting of emerging technologies, Conley will speak to how a CFO should consider IP as a company’s most valuable asset, including avoiding the cost-center trap and explaining why a diversified, strategically developed IP portfolio can be the key to an organization’s success. He will also highlight how Know Labs became a global IP leader in the non-invasive blood glucose monitoring category and the biggest challenges currently facing IP leaders.

“From my decades of experience in the IP space, I have developed a deep understanding of the correlation between patent leadership and value creation, and I am eager to delve into this topic with my colleagues at IPBC,” said Mr. Conley. “At Know Labs, patents and IP are the bedrock of our strategy for industry leadership. From this discussion, I’m hopeful my unique perspective can inform other leaders about how these essential roles can work harmoniously together and create sustainable competitive advantage and long-term shareholder value.”

Mr. Conley has spearheaded Know Labs’ IP strategy for the past three years as the company continues to expand its industry-leading patent portfolio. As of March 31, 2023, Know Labs has been ranked by ipCapital Group, a leading patent analytics firm, as the number one patent holder in non-invasive glucose monitoring with more than 159 patents issued and pending, a 62 percent increase from 2022’s year-end total of 98 patents issued and pending. This increase reinforces Know Labs’ goal of positioning itself as the leading worldwide IP holder in non-invasive blood glucose monitoring, and leveraging IP as key to its foundational business strategy. Currently, blood glucose monitoring is the company’s clinical focus; however, the extensive patent portfolio for its Bio-RFID™ technology platform reflects more expansive applications in areas across medical diagnostics, clinical research and industrial analytics.

Mr. Conley’s panel discussion will take place on June 14^th from 1 – 2 p.m. PT at IPBC Global 2023 in San Diego, CA. For more information on his session, visit events.iam-media.com/event/. To learn more about Know Labs, visit https://www.knowlabs.co/.

About Know Labs, Inc.

Know Labs, Inc. is a public company whose shares trade on the NYSE American Exchange under the stock symbol “KNW.” The Company’s technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The Company refers to its technology as Bio-RFID™. The Bio-RFID technology can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent-pending technology makes it possible to effectively identify and monitor analytes that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The first application of our Bio-RFID technology will be in a product marketed as a non-invasive glucose monitor. It will provide the user with real-time information on blood glucose levels. This product will require U.S. Food and Drug Administration clearance prior to its introduction to the market.

Safe Harbor Statement

This release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy; and (iv) performance of products. You can identify these statements by the use of the words “may,” “will,” “could,” “should,” “would,” “plans,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” “likely,” “forecast,” “probable,” “potential,” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. These risks and uncertainties also include such additional risk factors as are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended September 30, 2022, Forms 10-Q and 8-K, and in other filings we make with the Securities and Exchange Commission from time to time. These documents are available on the SEC Filings section of the Investor Relations section of our website at www.knowlabs.co. The Company cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005163/en/